MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-025-04148-0

Медицинская библиотека · International journal of hematology · 2026

Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL.

Yamaguchi Kohei, Yamauchi Takuji, Hirakawa Seiya, Nakagaki Hidetaka, Nishihara Hakuei, Shimo Masatoshi, Sasaki Kensuke, Sakoda Teppei, Jinnouchi Fumiaki, Miyawaki Kohta, Shima Takahiro, Kikushige Yoshikane, Mori Yasuo, Akashi Koichi, Kato Koji

СтатьяПеревод пока не подготовлен

Аннотация

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma characterized by 9p24.1 copy-number alterations and PD-1-mediated immune evasion. This profile confers high sensitivity to PD-1 inhibitors such as pembrolizumab. CD19-directed chimeric antigen receptor (CAR) T-cell therapies have shown benefit in relapsed or refractory (R/R) PMBCL, but their optimal role remains undefined. We retrospectively analyzed 31 patients with R/R B-cell lymphoma treated with lisocabtagene maraleucel (liso-cel), including four with PMBCL who received pembrolizumab prior to CAR-T. All four achieved remission before infusion, and three maintained durable complete responses (≥ 30 months). Toxicities were comparable to those in patients not treated with pembrolizumab, although one pembrolizumab-treated patient experienced fatal neurotoxicity. Favorable hematologic recovery and preserved T-cell counts at leukapheresis suggest that preceding PD-1 blockade did not compromise CAR-T manufacturing and may have enhanced T-cell fitness. These findings suggest that sequential PD-1 blockade followed by liso-cel is clinically feasible and may improve outcomes by leveraging the immune vulnerability of PMBCL. While prior studies have focused on axicabtagene ciloleucel, this report provides the first real-world data supporting the feasibility and potential benefit of this approach with liso-cel. Prospective studies are needed to confirm efficacy, safety, and optimal sequencing.

Для цитирования: Yamaguchi Kohei, Yamauchi Takuji, Hirakawa Seiya, Nakagaki Hidetaka, Nishihara Hakuei, Shimo Masatoshi, Sasaki Kensuke, Sakoda Teppei, Jinnouchi Fumiaki, Miyawaki Kohta, Shima Takahiro, Kikushige Yoshikane, Mori Yasuo, Akashi Koichi, Kato Koji. Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL.. International journal of hematology. 2026. DOI: 10.1007/s12185-025-04148-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.